{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T18:35:20Z","timestamp":1774982120835,"version":"3.50.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s00415-025-13321-8","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T18:19:57Z","timestamp":1756145997000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cerebrospinal fluid levels of chitinase 3-like 1 and interleukin-6 can predict response to platform therapies in relapsing multiple sclerosis"],"prefix":"10.1007","volume":"272","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5747-9169","authenticated-orcid":false,"given":"Guillaume","family":"Mathey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"Alix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Julien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Estelle","family":"Nisse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Pittion-Vouyovitch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chlo\u00e9","family":"Prunis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Malaplate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,25]]},"reference":[{"key":"13321_CR1","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","volume":"77","author":"G Luna","year":"2020","unstructured":"Luna G, Alping P, Burman J et al (2020) Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol 77:184\u2013191. https:\/\/doi.org\/10.1001\/jamaneurol.2019.3365","journal-title":"JAMA Neurol"},{"key":"13321_CR2","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1212\/WNL.0000000000006810","volume":"92","author":"C Gasperini","year":"2019","unstructured":"Gasperini C, Prosperini L, Tintor\u00e9 M et al (2019) Unraveling treatment response in multiple sclerosis: a clinical and MRI challenge. Neurology 92:180\u2013192. https:\/\/doi.org\/10.1212\/WNL.0000000000006810","journal-title":"Neurology"},{"key":"13321_CR3","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1177\/1352458517751049","volume":"24","author":"X Montalban","year":"2018","unstructured":"Montalban X, Gold R, Thompson AJ et al (2018) ECTRIMS\/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler 24:96\u2013120. https:\/\/doi.org\/10.1177\/1352458517751049","journal-title":"Mult Scler"},{"key":"13321_CR4","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1001\/jamaneurol.2021.2738","volume":"78","author":"T Spelman","year":"2021","unstructured":"Spelman T, Magyari M, Piehl F et al (2021) Treatment escalation vs immediate initiation of highly effective treatment for patients with relapsing\u2013remitting multiple sclerosis: data from 2 different national strategies. JAMA Neurol 78:1197\u20131204. https:\/\/doi.org\/10.1001\/jamaneurol.2021.2738","journal-title":"JAMA Neurol"},{"key":"13321_CR5","doi-asserted-by":"publisher","first-page":"1162340","DOI":"10.3389\/fimmu.2023.1162340","volume":"14","author":"J Temmerman","year":"2023","unstructured":"Temmerman J, Engelborghs S, Bjerke M, D\u2019haeseleer M (2023) Cerebrospinal fluid inflammatory biomarkers for disease progression in Alzheimer\u2019s disease and multiple sclerosis: a systematic review. Front Immunol 14:1162340. https:\/\/doi.org\/10.3389\/fimmu.2023.1162340","journal-title":"Front Immunol"},{"key":"13321_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30470-2","author":"AJ Thompson","year":"2017","unstructured":"Thompson AJ, Banwell BL, Barkhof F et al (2017) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. https:\/\/doi.org\/10.1016\/S1474-4422(17)30470-2","journal-title":"Lancet Neurol"},{"key":"13321_CR7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2147\/DNND.S98936","volume":"7","author":"VK Harris","year":"2017","unstructured":"Harris VK, Tuddenham JF, Sadiq SA (2017) Biomarkers of multiple sclerosis: current findings. Degener Neurol Neuromuscul Dis 7:19\u201329. https:\/\/doi.org\/10.2147\/DNND.S98936","journal-title":"Degener Neurol Neuromuscul Dis"},{"key":"13321_CR8","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1093\/brain\/awq035","volume":"133","author":"M Comabella","year":"2010","unstructured":"Comabella M, Fern\u00e1ndez M, Martin R et al (2010) Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain 133:1082\u20131093. https:\/\/doi.org\/10.1093\/brain\/awq035","journal-title":"Brain"},{"key":"13321_CR9","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s12035-022-03060-6","volume":"60","author":"M Lucchini","year":"2023","unstructured":"Lucchini M, De Arcangelis V, Piro G et al (2023) CSF CXCL13 and chitinase 3-like-1 levels predict disease course in relapsing multiple sclerosis. Mol Neurobiol 60:36\u201350. https:\/\/doi.org\/10.1007\/s12035-022-03060-6","journal-title":"Mol Neurobiol"},{"key":"13321_CR10","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1177\/1352458514561906","volume":"21","author":"G Hinsinger","year":"2015","unstructured":"Hinsinger G, Gal\u00e9otti N, Nabholz N et al (2015) Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis. Mult Scler 21:1251\u20131261. https:\/\/doi.org\/10.1177\/1352458514561906","journal-title":"Mult Scler"},{"key":"13321_CR11","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1177\/1352458514549397","volume":"21","author":"MAM Mart\u00ednez","year":"2015","unstructured":"Mart\u00ednez MAM, Olsson B, Bau L et al (2015) Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis. Mult Scler 21:550\u2013561. https:\/\/doi.org\/10.1177\/1352458514549397","journal-title":"Mult Scler"},{"key":"13321_CR12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jneuroim.2014.02.004","volume":"269","author":"C Malmestr\u00f6m","year":"2014","unstructured":"Malmestr\u00f6m C, Axelsson M, Lycke J et al (2014) CSF levels of YKL-40 are increased in MS and replaces with immunosuppressive treatment. J Neuroimmunol 269:87\u201389. https:\/\/doi.org\/10.1016\/j.jneuroim.2014.02.004","journal-title":"J Neuroimmunol"},{"key":"13321_CR13","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1177\/1352458516639384","volume":"23","author":"L Novakova","year":"2017","unstructured":"Novakova L, Axelsson M, Khademi M et al (2017) Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis. Mult Scler 23:62\u201371. https:\/\/doi.org\/10.1177\/1352458516639384","journal-title":"Mult Scler"},{"key":"13321_CR14","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jneuroim.2016.12.006","volume":"303","author":"C Matute-Blanch","year":"2017","unstructured":"Matute-Blanch C, R\u00edo J, Villar LM et al (2017) Chitinase 3-like 1 is associated with the response to interferon-beta treatment in multiple sclerosis. J Neuroimmunol 303:62\u201365. https:\/\/doi.org\/10.1016\/j.jneuroim.2016.12.006","journal-title":"J Neuroimmunol"},{"key":"13321_CR15","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1177\/1352458509359725","volume":"16","author":"J Salzer","year":"2010","unstructured":"Salzer J, Svenningsson A, Sundstr\u00f6m P (2010) Neurofilament light as a prognostic marker in multiple sclerosis. Mult Scler 16:287\u2013292. https:\/\/doi.org\/10.1177\/1352458509359725","journal-title":"Mult Scler"},{"key":"13321_CR16","doi-asserted-by":"publisher","first-page":"e1007","DOI":"10.1212\/WNL.0000000000007032","volume":"92","author":"J Kuhle","year":"2019","unstructured":"Kuhle J, Kropshofer H, Haering DA et al (2019) Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Neurology 92:e1007\u2013e1015. https:\/\/doi.org\/10.1212\/WNL.0000000000007032","journal-title":"Neurology"},{"key":"13321_CR17","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1136\/jnnp-2019-321321","volume":"90","author":"T Sejbaek","year":"2019","unstructured":"Sejbaek T, Nielsen HH, Penner N et al (2019) Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment na\u00efve relapsing MS patients. J Neurol Neurosurg Psychiatry 90:1324\u20131330. https:\/\/doi.org\/10.1136\/jnnp-2019-321321","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"13321_CR18","doi-asserted-by":"publisher","first-page":"312","DOI":"10.3390\/biomedicines8090312","volume":"8","author":"A Huss","year":"2020","unstructured":"Huss A, Senel M, Abdelhak A et al (2020) Longitudinal serum neurofilament levels of multiple sclerosis patients before and after treatment with first-line immunomodulatory therapies. Biomedicines 8:312. https:\/\/doi.org\/10.3390\/biomedicines8090312","journal-title":"Biomedicines"},{"key":"13321_CR19","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1177\/1352458520986956","volume":"27","author":"RJ Fox","year":"2021","unstructured":"Fox RJ, Raska P, Barro C et al (2021) Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis. Mult Scler 27:2014\u20132022. https:\/\/doi.org\/10.1177\/1352458520986956","journal-title":"Mult Scler"},{"key":"13321_CR20","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/j.bbamcr.2016.03.018","volume":"1863","author":"M Rothaug","year":"2016","unstructured":"Rothaug M, Becker-Pauly C, Rose-John S (2016) The role of interleukin-6 signaling in nervous tissue. Biochim Biophys Acta 1863:1218\u20131227. https:\/\/doi.org\/10.1016\/j.bbamcr.2016.03.018","journal-title":"Biochim Biophys Acta"},{"key":"13321_CR21","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/758314","volume":"2015","author":"A Malekzadeh","year":"2015","unstructured":"Malekzadeh A, Van de Geer-Peeters W, De Groot V et al (2015) Fatigue in patients with multiple sclerosis: is it related to pro- and anti-inflammatory cytokines? Dis Markers 2015:758314. https:\/\/doi.org\/10.1155\/2015\/758314","journal-title":"Dis Markers"},{"key":"13321_CR22","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s11011-019-00452-x","volume":"34","author":"V Fominykh","year":"2019","unstructured":"Fominykh V, Brylev L, Gaskin V et al (2019) Neuronal damage and neuroinflammation markers in patients with autoimmune encephalitis and multiple sclerosis. Metab Brain Dis 34:1473\u20131485. https:\/\/doi.org\/10.1007\/s11011-019-00452-x","journal-title":"Metab Brain Dis"},{"key":"13321_CR23","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3389\/fncel.2020.00120","volume":"14","author":"M Stampanoni Bassi","year":"2020","unstructured":"Stampanoni Bassi M, Iezzi E, Drulovic J et al (2020) IL-6 in the cerebrospinal fluid signals disease activity in multiple sclerosis. Front Cell Neurosci 14:120. https:\/\/doi.org\/10.3389\/fncel.2020.00120","journal-title":"Front Cell Neurosci"},{"key":"13321_CR24","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12974-022-02443-9","volume":"19","author":"M-H Dong","year":"2022","unstructured":"Dong M-H, Zhou L-Q, Tang Y et al (2022) CSF sTREM2 in neurological diseases: a two-sample Mendelian randomization study. J Neuroinflammation 19:79. https:\/\/doi.org\/10.1186\/s12974-022-02443-9","journal-title":"J Neuroinflammation"},{"key":"13321_CR25","doi-asserted-by":"publisher","first-page":"205521732110197","DOI":"10.1177\/20552173211019772","volume":"7","author":"ZA Ioannides","year":"2021","unstructured":"Ioannides ZA, Csurhes PA, Swayne A et al (2021) Correlations between macrophage\/microglial activation marker sTREM-2 and measures of T-cell activation, neuroaxonal damage and disease severity in multiple sclerosis. Mult Scler J Exp Transl Clin 7:20552173211019772. https:\/\/doi.org\/10.1177\/20552173211019772","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"13321_CR26","doi-asserted-by":"publisher","first-page":"222","DOI":"10.3390\/biom12020222","volume":"12","author":"F Azzolini","year":"2022","unstructured":"Azzolini F, Gilio L, Pavone L et al (2022) Neuroinflammation is associated with GFAP and sTREM2 levels in multiple sclerosis. Biomolecules 12:222. https:\/\/doi.org\/10.3390\/biom12020222","journal-title":"Biomolecules"},{"key":"13321_CR27","doi-asserted-by":"publisher","first-page":"575","DOI":"10.3389\/fncel.2019.00575","volume":"13","author":"G Chapman","year":"2019","unstructured":"Chapman G, Shanmugalingam U, Smith PD (2019) The role of neuronal pentraxin 2 (NP2) in regulating glutamatergic signaling and neuropathology. Front Cell Neurosci 13:575. https:\/\/doi.org\/10.3389\/fncel.2019.00575","journal-title":"Front Cell Neurosci"},{"key":"13321_CR28","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/mds.29287","volume":"38","author":"J Nilsson","year":"2023","unstructured":"Nilsson J, Constantinescu J, Nellg\u00e5rd B et al (2023) Cerebrospinal fluid biomarkers of synaptic dysfunction are altered in Parkinson\u2019s disease and related disorders. Mov Disord 38:267\u2013277. https:\/\/doi.org\/10.1002\/mds.29287","journal-title":"Mov Disord"},{"key":"13321_CR29","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1002\/alz.12353","volume":"17","author":"O Libiger","year":"2021","unstructured":"Libiger O, Shaw LM, Watson MH et al (2021) Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer\u2019s disease. Alzheimers Dement 17:1976\u20131987. https:\/\/doi.org\/10.1002\/alz.12353","journal-title":"Alzheimers Dement"},{"key":"13321_CR30","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1002\/ana.26725","volume":"94","author":"A Soldan","year":"2023","unstructured":"Soldan A, Oh S, Ryu T et al (2023) NPTX2 in cerebrospinal fluid predicts the progression from normal cognition to mild cognitive impairment. Ann Neurol 94:620\u2013631. https:\/\/doi.org\/10.1002\/ana.26725","journal-title":"Ann Neurol"},{"key":"13321_CR31","doi-asserted-by":"publisher","first-page":"18310","DOI":"10.1038\/s41598-023-45384-w","volume":"13","author":"P Ducatel","year":"2023","unstructured":"Ducatel P, Debouverie M, Soudant M et al (2023) Performance of administrative databases for identifying individuals with multiple sclerosis. Sci Rep 13:18310. https:\/\/doi.org\/10.1038\/s41598-023-45384-w","journal-title":"Sci Rep"},{"key":"13321_CR32","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1136\/jnnp.55.8.671","volume":"55","author":"C Confavreux","year":"1992","unstructured":"Confavreux C, Compston DA, Hommes OR et al (1992) EDMUS, a European database for multiple sclerosis. J Neurol Neurosurg Psychiatry 55:671\u2013676","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"13321_CR33","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1177\/1352458515574148","volume":"21","author":"S Modvig","year":"2015","unstructured":"Modvig S, Degn M, Roed H et al (2015) Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis. Mult Scler 21:1761\u20131770. https:\/\/doi.org\/10.1177\/1352458515574148","journal-title":"Mult Scler"},{"key":"13321_CR34","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1471-2105-12-77","volume":"12","author":"X Robin","year":"2011","unstructured":"Robin X, Turck N, Hainard A et al (2011) pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 12:77. https:\/\/doi.org\/10.1186\/1471-2105-12-77","journal-title":"BMC Bioinformatics"},{"key":"13321_CR35","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.patrec.2005.10.010","volume":"27","author":"T Fawcett","year":"2006","unstructured":"Fawcett T (2006) An introduction to ROC analysis. Pattern Recogn Lett 27:861\u2013874. https:\/\/doi.org\/10.1016\/j.patrec.2005.10.010","journal-title":"Pattern Recogn Lett"},{"key":"13321_CR36","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/jnc.13881","volume":"141","author":"L Novakova","year":"2017","unstructured":"Novakova L, Axelsson M, Khademi M et al (2017) Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing\u2013remitting multiple sclerosis. J Neurochem 141:296\u2013304. https:\/\/doi.org\/10.1111\/jnc.13881","journal-title":"J Neurochem"},{"key":"13321_CR37","doi-asserted-by":"publisher","first-page":"1343892","DOI":"10.3389\/fimmu.2024.1343892","volume":"15","author":"D Marastoni","year":"2024","unstructured":"Marastoni D, Foschi M, Eccher C et al (2024) CSF levels of chitinase3like1 correlate with early response to cladribine in multiple sclerosis. Front Immunol 15:1343892. https:\/\/doi.org\/10.3389\/fimmu.2024.1343892","journal-title":"Front Immunol"},{"key":"13321_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0270607","volume":"17","author":"M Petr\u017ealka","year":"2022","unstructured":"Petr\u017ealka M, Meluz\u00ednov\u00e1 E, Libert\u00ednov\u00e1 J et al (2022) IL-2, IL-6 and chitinase 3-like 2 might predict early relapse activity in multiple sclerosis. PLoS ONE 17:e0270607. https:\/\/doi.org\/10.1371\/journal.pone.0270607","journal-title":"PLoS ONE"},{"key":"13321_CR39","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.3390\/cells13242086","volume":"13","author":"I Jatczak-Pawlik","year":"2024","unstructured":"Jatczak-Pawlik I, Jurewicz A, Domowicz M et al (2024) CHI3L1 in multiple sclerosis-from bench to clinic. Cells 13:2086. https:\/\/doi.org\/10.3390\/cells13242086","journal-title":"Cells"},{"key":"13321_CR40","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1177\/1352458518767043","volume":"25","author":"E Thouvenot","year":"2019","unstructured":"Thouvenot E, Hinsinger G, Demattei C et al (2019) Cerebrospinal fluid chitinase-3-like protein 1 level is not an independent predictive factor for the risk of clinical conversion in radiologically isolated syndrome. Mult Scler 25:669\u2013677. https:\/\/doi.org\/10.1177\/1352458518767043","journal-title":"Mult Scler"},{"key":"13321_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.649876","volume":"15","author":"R Masvekar","year":"2021","unstructured":"Masvekar R, Phillips J, Komori M et al (2021) Cerebrospinal fluid biomarkers of myeloid and glial cell activation are correlated with multiple sclerosis lesional inflammatory activity. Front Neurosci 15:649876. https:\/\/doi.org\/10.3389\/fnins.2021.649876","journal-title":"Front Neurosci"},{"key":"13321_CR42","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1111\/ene.13975","volume":"26","author":"T Chazal","year":"2019","unstructured":"Chazal T, Costopoulos M, Maillart E et al (2019) The cerebrospinal fluid CD4\/CD8 ratio and interleukin-6 and -10 levels in neurosarcoidosis: a multicenter, pragmatic, comparative study. Eur J Neurol 26:1274\u20131280. https:\/\/doi.org\/10.1111\/ene.13975","journal-title":"Eur J Neurol"},{"key":"13321_CR43","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1002\/ana.25197","volume":"83","author":"R Magliozzi","year":"2018","unstructured":"Magliozzi R, Howell OW, Nicholas R et al (2018) Inflammatory intrathecal profiles and cortical damage in multiple sclerosis. Ann Neurol 83:739\u2013755. https:\/\/doi.org\/10.1002\/ana.25197","journal-title":"Ann Neurol"},{"key":"13321_CR44","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1007\/s00415-018-8994-5","volume":"265","author":"M Stampanoni Bassi","year":"2018","unstructured":"Stampanoni Bassi M, Iezzi E, Landi D et al (2018) Delayed treatment of MS is associated with high CSF levels of IL-6 and IL-8 and worse future disease course. J Neurol 265:2540\u20132547. https:\/\/doi.org\/10.1007\/s00415-018-8994-5","journal-title":"J Neurol"},{"key":"13321_CR45","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1093\/brain\/awv017","volume":"138","author":"E Cant\u00f3","year":"2015","unstructured":"Cant\u00f3 E, Tintor\u00e9 M, Villar LM et al (2015) Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. Brain 138:918\u2013931. https:\/\/doi.org\/10.1093\/brain\/awv017","journal-title":"Brain"},{"key":"13321_CR46","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1007\/s00415-023-12135-w","volume":"271","author":"P Arroyo Pereiro","year":"2024","unstructured":"Arroyo Pereiro P, Mu\u00f1oz-Vendrell A, Le\u00f3n Moreno I et al (2024) Baseline serum neurofilament light chain levels differentiate aggressive from benign forms of relapsing\u2013remitting multiple sclerosis: a 20-year follow-up cohort. J Neurol 271:1599\u20131609. https:\/\/doi.org\/10.1007\/s00415-023-12135-w","journal-title":"J Neurol"},{"key":"13321_CR47","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200427","volume":"12","author":"A Bar-Or","year":"2025","unstructured":"Bar-Or A, Nicholas J, Feng J et al (2025) Exploring the clinical utility of neurofilament light chain assays in multiple sclerosis management. Neurol Neuroimmunol Neuroinflamm 12:e200427. https:\/\/doi.org\/10.1212\/NXI.0000000000200427","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"13321_CR48","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16077","volume":"31","author":"L Midaglia","year":"2024","unstructured":"Midaglia L, Rovira A, Mir\u00f3 B et al (2024) Association of magnetic resonance imaging phenotypes and serum biomarker levels with treatment response and long-term disease outcomes in multiple sclerosis patients. Eur J Neurol 31:e16077. https:\/\/doi.org\/10.1111\/ene.16077","journal-title":"Eur J Neurol"},{"key":"13321_CR49","doi-asserted-by":"publisher","DOI":"10.1177\/1352458518794308","author":"F Sellebjerg","year":"2018","unstructured":"Sellebjerg F, Royen L, Soelberg S\u00f8rensen P et al (2018) Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis. Mult Scler. https:\/\/doi.org\/10.1177\/1352458518794308","journal-title":"Mult Scler"},{"key":"13321_CR50","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jneuroim.2016.08.004","volume":"299","author":"MA Ma\u00f1\u00e9-Mart\u00ednez","year":"2016","unstructured":"Ma\u00f1\u00e9-Mart\u00ednez MA, Olsson B, Bau L et al (2016) Glial and neuronal markers in cerebrospinal fluid in different types of multiple sclerosis. J Neuroimmunol 299:112\u2013117. https:\/\/doi.org\/10.1016\/j.jneuroim.2016.08.004","journal-title":"J Neuroimmunol"},{"key":"13321_CR51","doi-asserted-by":"publisher","DOI":"10.1177\/20552173231169463","author":"G Cutter","year":"2023","unstructured":"Cutter G, Rudick RA, de Moor C et al (2023) Serum neurofilament light-chain levels and long-term treatment outcomes in relapsing\u2013remitting multiple sclerosis patients: a post hoc analysis of the randomized CombiRx trial. Mult Scler J Exp Transl Clin. https:\/\/doi.org\/10.1177\/20552173231169463","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"13321_CR52","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1002\/ana.25786","volume":"88","author":"R Magliozzi","year":"2020","unstructured":"Magliozzi R, Scalfari A, Pisani AI et al (2020) The CSF profile linked to cortical damage predicts multiple sclerosis activity. Ann Neurol 88:562\u2013573. https:\/\/doi.org\/10.1002\/ana.25786","journal-title":"Ann Neurol"},{"key":"13321_CR53","doi-asserted-by":"publisher","DOI":"10.1177\/17562864221092124","author":"D Marastoni","year":"2022","unstructured":"Marastoni D, Pisani AI, Schiavi G et al (2022) CSF TNF and osteopontin levels correlate with the response to dimethyl fumarate in early multiple sclerosis. Ther Adv Neurol Disord. https:\/\/doi.org\/10.1177\/17562864221092124","journal-title":"Ther Adv Neurol Disord"},{"key":"13321_CR54","doi-asserted-by":"publisher","DOI":"10.1177\/1756286420970833","author":"M Stampanoni Bassi","year":"2020","unstructured":"Stampanoni Bassi M, Drulovic J, Pekmezovic T et al (2020) Cerebrospinal fluid inflammatory biomarkers predicting interferon-beta response in MS patients. Ther Adv Neurol Disord. https:\/\/doi.org\/10.1177\/1756286420970833","journal-title":"Ther Adv Neurol Disord"},{"key":"13321_CR55","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200050","volume":"10","author":"N Fissolo","year":"2023","unstructured":"Fissolo N, Pappolla A, Rio J et al (2023) Serum levels of CXCL13 are associated with teriflunomide response in patients with multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 10:e200050. https:\/\/doi.org\/10.1212\/NXI.0000000000200050","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"13321_CR56","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","volume":"391","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Baranzini SE, Geurts J et al (2018) Multiple sclerosis. Lancet 391:1622\u20131636. https:\/\/doi.org\/10.1016\/S0140-6736(18)30481-1","journal-title":"Lancet"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13321-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13321-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13321-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T10:35:09Z","timestamp":1760524509000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13321-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,25]]},"references-count":56,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["13321"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13321-8","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,25]]},"assertion":[{"value":"22 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"GM, TA, MJ, CP, SPV, MD, JE, and CM declare that there is no other conflict of interest in line with this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"592"}}